Transactions

ADVANZ PHARMA Corp. Limited, a portfolio company of Nordic Capital, acquisition of the ex-U.S. primary biliary cholangitis business from Intercept Pharmaceuticals Inc.

Date Announced:
05/05/2022

client:
ADVANZ PHARMA Corp. Limited

Status:
Closed – 07/01/2022

Value:
Up to $450 million